Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $4.06 in the prior trading day, Taysha Gene Therapies Inc (NASDAQ: TSHA) closed at $4.49, up 10.59%. In other words, the price has increased by $10.59 from its previous closing price. On the day, 2.56 million shares were traded. TSHA stock price reached its highest trading level at $4.515 during the session, while it also had its lowest trading level at $4.1.
Ratios:
Our goal is to gain a better understanding of TSHA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.47 and its Current Ratio is at 10.47. In the meantime, Its Debt-to-Equity ratio is 0.32 whereas as Long-Term Debt/Eq ratio is at 0.31.
Upgrades & Downgrades
In the most recent recommendation for this company, Raymond James on October 21, 2025, initiated with a Strong Buy rating and assigned the stock a target price of $13.
On July 11, 2025, BofA Securities started tracking the stock assigning a Buy rating and target price of $8.
On June 27, 2024, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $5.BMO Capital Markets initiated its Outperform rating on June 27, 2024, with a $5 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 01 ’25 when Nagendran Sukumar sold 260,047 shares for $4.51 per share. The transaction valued at 1,172,812 led to the insider holds 1,006,439 shares of the business.
Nagendran Sukumar sold 110,125 shares of TSHA for $523,094 on Nov 28 ’25. The President and Head of R&D now owns 1,006,439 shares after completing the transaction at $4.75 per share. On Nov 28 ’25, another insider, Nagendran Sukumar, who serves as the Officer of the company, bought 370,172 shares for $4.86 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TSHA now has a Market Capitalization of 1229897856 and an Enterprise Value of 1001636992. For the stock, the TTM Price-to-Sale (P/S) ratio is 194.91 while its Price-to-Book (P/B) ratio in mrq is 5.62. Its current Enterprise Value per Revenue stands at 158.738 whereas that against EBITDA is -9.919.
Stock Price History:
The Beta on a monthly basis for TSHA is 1.03, which has changed by 0.7058823 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, TSHA has reached a high of $5.51, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is 1.76%, while the 200-Day Moving Average is calculated to be 57.60%.
Shares Statistics:
The stock has traded on average 6.39M shares per day over the past 3-months and 3210960 shares per day over the last 10 days, according to various share statistics. A total of 273.92M shares are outstanding, with a floating share count of 224.25M. Insiders hold about 18.13% of the company’s shares, while institutions hold 89.58% stake in the company. Shares short for TSHA as of 1763078400 were 48083858 with a Short Ratio of 7.53, compared to 1760486400 on 41975904. Therefore, it implies a Short% of Shares Outstanding of 48083858 and a Short% of Float of 19.610001.
Earnings Estimates
A comprehensive evaluation of Taysha Gene Therapies Inc (TSHA) is underway, with the input of 5 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.07 and low estimates of -$0.12.
Analysts are recommending an EPS of between -$0.24 and -$0.38 for the fiscal current year, implying an average EPS of -$0.34. EPS for the following year is -$0.44, with 5.0 analysts recommending between -$0.29 and -$0.54.
Revenue Estimates
A total of 13 analysts have provided revenue estimates for TSHA’s current fiscal year. The highest revenue estimate was $15M, while the lowest revenue estimate was $4M, resulting in an average revenue estimate of $6.3M. In the same quarter a year ago, actual revenue was $8.33M
